Hara Yoshiaki, Kitazawa Yusuke, Funeshima Naoko, Kawasaki Mikiko, Sato Yoshinobu, Tezuka Katsunari, Kimura Hiromitsu, Hatakeyama Katsuyoshi, Li Xiao-Kang
Laboratory of Transplantation Immunology, National Research Institute for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan.
Int Immunopharmacol. 2006 Jul;6(7):1143-51. doi: 10.1016/j.intimp.2006.02.008. Epub 2006 Mar 6.
Regulatory cells may play a pivotal role in inducing and maintaining transplantation tolerance. We investigated the mechanism of anergic lymphocytes with regulatory cell potential generated in vitro by ICOS and CD 28 co-stimulatory blockades as a source of cellular therapy for treating allograft rejection. Anergic lymphocytes were generated by a mixed lymphocyte reaction consisting of DA splenocytes as the stimulator and Lewis splenocytes as the responder in the presence of anti-ICOS mAb and rCTLA-4I g. Immunoregulatory effects of these lymphocytes were evaluated by secondary MLR and using other various stimulations. DA heart was transplanted into 7.5 Gy-irradiated Lewis rat after intravenous administration of these cells and/or Lewis spleen lymphocytes. We observed that these lymphocytes were not only anergic to alloantigen and polyclonal stimulations but also exhibited regulative activity to inhibit the alloreactive T-cell response. Our adoptive transfer studies revealed that irradiated recipients that received both anergic lymphocytes and naIve Lewis lymphocytes had significantly prolonged DA cardiac graft survival (mean 17.5 days) compared with a group that received Lewis lymphocytes alone (mean 10.8 days). Furthermore, some of the recipients accepted the graft indefinitely after receiving anergic lymphocytes alone (>100 days). These results demonstrated that anergic lymphocytes with regulatory activities can be generated through blocking co-stimulatory signals, CD 28 and ICOS, simultaneously in vitro, and may advance a new immunomodulatory strategy for preventing allorejection in organ transplantation.
调节性细胞可能在诱导和维持移植耐受中起关键作用。我们研究了通过ICOS和CD28共刺激阻断在体外产生的具有调节细胞潜能的无反应性淋巴细胞作为细胞治疗来源用于治疗同种异体移植排斥反应的机制。无反应性淋巴细胞是在抗ICOS单克隆抗体和重组CTLA-4Ig存在的情况下,由以DA脾细胞为刺激细胞、Lewis脾细胞为反应细胞的混合淋巴细胞反应产生的。通过二次混合淋巴细胞反应和使用其他各种刺激来评估这些淋巴细胞的免疫调节作用。在静脉注射这些细胞和/或Lewis脾淋巴细胞后,将DA心脏移植到经7.5 Gy照射的Lewis大鼠体内。我们观察到这些淋巴细胞不仅对同种异体抗原和多克隆刺激无反应,而且还表现出调节活性以抑制同种异体反应性T细胞反应。我们的过继转移研究表明,与仅接受Lewis淋巴细胞的组(平均10.8天)相比,接受无反应性淋巴细胞和未活化Lewis淋巴细胞的受照射受体的DA心脏移植物存活时间显著延长(平均17.5天)。此外,一些受体在仅接受无反应性淋巴细胞后(>100天)无限期地接受了移植物。这些结果表明,通过在体外同时阻断共刺激信号CD28和ICOS,可以产生具有调节活性的无反应性淋巴细胞,这可能为预防器官移植中的同种异体排斥反应推进一种新的免疫调节策略。